Background:

Liraglutide is aglucagon-like peptide-1(GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Liraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1. Liraglutide is an injectable drug for the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells^[1].

参考文献:
1. Wang Y,et al. Transformation of oligomers of lipidated peptide induced by change in pH.Mol Pharm. 2015 Feb 2;12(2):411-9.